Protein Fluidics is commercializing new microfluidic systems for bio-sample analysis in order to accelerate data driven decisions. We are passionate about providing scientists with the latest technologies to help them create the next generation of therapeutics. The company is located in the San Francisco Bay Area and run by an experienced team of scientists, engineers, and industry executives. It is privately held and has closed two rounds of funding from strategic investors.
Evan F Cromwell, Ph.D.
President and CEO
Evan has over 30 years of senior executive and technical expertise in numerous hi-tech industries. He has piloted the design, development, and manufacture of systems for biological assays, materials analysis, optical inspection, and process control. Prior to Protein Fluidic, Evan served as the President and CEO of California-based Blueshift Biotechnologies. This high-content screening and analysis venture was acquired by Molecular Devices in 2008. After the acquisition, Evan remained onboard at Molecular Devices, which became part of Danaher Life Sciences, where he further honed his business and entrepreneurial acumen. In addition to co-founding successful start-ups, Evan has chaired several scientific advisory boards and led global technology development initiatives. Evan’s passion is integrating new technologies into products that provide unexpected value to customers in life sciences and other communities.
Evan holds a B.S. in Chemistry from Caltech, and earned his Ph.D. in Physical Chemistry in the laboratory of Nobel Laureate Yuan-Tseh Lee at the University of California, Berkeley. He has authored 40+ publications in the fields of biology, physical chemistry, and optical instrumentation and holds 15 patents.
Vice President of Product Development
Wilson has over 20 years of engineering experience in creating innovative, cutting-edge analytical systems for bioresearch and medical device industries. His portfolio includes leading roles in systems design and mechanical engineering at several bay area companies such as Molecular Devices, Fluxion Biosciences, and Cutera. Wilson excels in merging the fields of fluidics, optics, electronics, and precision injection-molding to create innovative systems for clinical diagnostics, drug discovery, and medical devices. His talents extend beyond just development of robust platforms as Wilson has successfully launched and commercialized five instruments over the past 10 years. His specialty is crafting elegant solutions to challenging design criteria that balance the needs of the customer, R & D, sales and marketing, and manufacturing.
Wilson earned his B.S. in Mechanical Engineering from the University of California, Berkeley.
Neil Bristol, M.S.
Director of Sales and Marketing
Neil has been entwined in the diagnostics, bio-detection and imaging industry for over 25 years. He began his life sciences journey as a bench scientist in R & D and product development for 10 years before transitioning into sales and marketing. Neil has led successful product launches at Digene, LJL Biosystems, Molecular Devices, Blueshift Technologies, and Guava Technologies. He brings solvent, compelling expertise about the high-content, bio-imaging, and drug discovery markets. Neil appreciates the challenge of advancing and optimizing new tools in automation, instrumentation, and assays.
Neil completed his B.S. in Microbiology from the University of Maryland, College Park, and his M.S. in Biotechnology from Johns Hopkins University.
Hong Jiao, Ph.D.
Chief Scientific Advisor
Hong has 25+ years of ingenuity in creating novel tools for the life sciences, medical device, data storage, and telecom industries. He has put his expertise to use by leading various R & D teams in analytical chemistry, microfluidics, robotics, and instrumentation. In 2011, Hong founded the Berkeley-based venture HJ Science & Technology (HJST) as a conduit for the rapid prototyping and commercialization of microscale automation-based technology. HJST excels in creating innovative, real-time portable tools that rival accepted industry standards. HJST-based platforms have diverse applications from life sciences and medical diagnostics, to analytical chemistry and environmental monitoring. Their current research priorities include immunoassays, synthetic biology, analytical chemistry, and genetic screening. Protein Fluidics has licensed key HJST technologies.
Hong has a B.S. in Engineering Physics from University of California, Berkeley, an M.S. in Applied Physics from Caltech, and a Ph.D. in Physics from MIT. He has won several federally-funded SBIR and technology grants from a wide range of agencies such as the DOA, DoD, EPA, NASA, and NSF.
April 6, 2016 Protein Fluidics closes Series seed round of investment
October 1, 2016 Protein Fluidics moves into new headquarters in Burlingame CA
May 4, 2018 Protein Fluidics announces the PuMA system